Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - Charles H . Adler, M.D., Ph.D.

Back to Research Profile

  1. Cobb SA, Wider C, Ross OA, Mata IF, Adler CH, Rajput A, Rajput AH, Wu RM, Hauser R, Josephs KA, Carr J, Gwinn K, Heckman MG, Aasly JO, Lynch T, Uitti RJ, Wszolek ZK, Kapatos G, Farrer MJ. GCH1 in early-onset Parkinson's disease. Mov Disord 2009 Oct 30; 24(14):2070-5.
    View PubMed
  2. Adler CH. Perioperative use of botulinum toxins. Toxicon 2009 Oct; 54(5 Special Issue SI):654-7.
    View PubMed
  3. Adler CH. Perioperative use of botulinum toxins. Toxicon 2009 Oct; 54(5):654-7. Epub 2008 Dec 03.
    View PubMed
  4. Driver-Dunckley E, Connor D, Hentz J, Sabbagh M, Silverberg N, Hernandez J, Vedders L, Evidente VG, Shill H, Caviness J, Adler C. No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome. Mov Disord 2009 Sep 15; 24(12):1840-2.
    View PubMed
  5. Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stem MB, Voon V. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2009 Jul 30; 24(10):1461-7.
    View PubMed
  6. Sabbagh MN, Adler CH, Lahti TJ, Connor DJ, Vedders L, Peterson LK, Caviness JN, Shill HA, Sue LI, Ziabreva I, Perry E, Ballard CG, Aarsland D, Walker DG, Beach TG. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009 Jul-Sep; 23(3):295-7.
    View PubMed
  7. Sabbagh MN, Sandhu SS, Farlow MR, Vedders L, Shill HA, Caviness JN, Connor DJ, Sue L, Adler CH, Beach TG. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord 2009 Jul-Sep; 23(3):229-33.
    View PubMed
  8. Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, Adler CH, Caviness JN, Wingerchuk DM. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist 2009 Jul; 15(4):234-7.
    View PubMed
  9. Vilarino-Guell C, Wider C, Soto-Ortolaza AI, Cobb SA, Kachergus JM, Keeling BH, Dachsel JC, Hulihan MM, Dickson DW, Wszolek ZK, Uitti RJ, Graff-Radford NR, Boeve BF, Josephs KA, Miller B, Boylan KB, Gwinn K, Adler CH, Aasly JO, Hentati F, Destee A, Characterization of DCTN1 genetic variability in neurodegeneration. Neurology 2009 Jun 9; 72(23):2024-8.
    View PubMed
  10. Beach TG, White CL III, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, Sue LI, Sasse J, Bachalakuri J, Henry-Watson J, Akiyama H, Adler CH. Olfactory bulb alpha -synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol (Berl) 2009 Feb; 117(2):169-74.
    View PubMed
  11. Alvarez MV, Driver-Dunckley EE, Caviness JN, Adler CH, Evidente VG. Case series of painful legs and moving toes: clinical and electrophysiologic observations. Mov Disord 2008 Oct 30; 23(14):2062-6.
    View PubMed
  12. Ludlow CL, Adler CH, Berke GS, Bielamowicz SA, Blitzer A, Bressman SB, Hallett M, Jinnah HA, Juergens U, Martin SB, Perlmutter JS, Sapienza C, Singleton A, Tanner CM, Woodson GE. Research priorities in spasmodic dysphonia. Otolaryngology - Head & Neck Surgery 2008 Oct; 139(4):495-505.
    View PubMed
  13. Sparks DL, Ziolkowski C, Connor D, Beach T, Adler C, Sabbagh M. Copper and cognition in Alzheimer's disease and Parkinson's disease. Cell Biology & Toxicology 2008 Oct; 24(5):426-30.
    View PubMed
  14. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Leverenz JB, Roncaroli F, Buttini M, Hladik CL, Sue LI, Noorigian JV, Adler CH. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008 Sep; 116(3):277-88. Epub 2008 Jul 15.
    View PubMed
  15. Stamper C, Siegel A, Liang WS, Pearson JV, Stephan DA, Shill H, Connor D, Caviness JN, Sabbagh M, Beach TG, Adler CH, Dunckley T. Neuronal gene expression correlates of Parkinson's disease with dementia. Mov Disord 2008 Aug 15; 23(11):1588-95.
    View PubMed
  16. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol 2008 Jun; 63(6):743-50.
    View PubMed
  17. Shill HA, Adler CH, Sabbagh MN, Connor DJ, Caviness JN, Hentz JG, Beach TG. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology 2008 Apr 15; 70(16 Pt 2):1452-5.
    View PubMed
  18. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Parkinson Study Group, Leurgans S. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008 Apr 15; 23(5):690-9.
    View PubMed
  19. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 2008 Apr; 115(4):445-51. Epub 2007 Nov 06.
    View PubMed
  20. McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders? Neurologist 2007 Nov; 13(6):382-5.
    View PubMed
  21. Beach TG, Sue LI, Walker DG, Lue LF, Connor DJ, Caviness JN, Sabbagh MN, Adler CH. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol (Berl) 2007 Oct; 114(4):419-24. Epub 2007 Jul 17.
    View PubMed
  22. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH. Gambling and increased sexual desire with dopaminergic medications in restless leg syndrome. Clin Neuropharmacol 2007 Sep/Oct; 30(5):249-255.
    View PubMed
  23. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, Krahn L, Adler CH. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007 Sep-Oct; 30(5):249-55.
    View PubMed
  24. Caviness JN, Hentz JG, Evidente VG, Driver-Dunckley E, Samanta J, Mahant P, Connor DJ, Sabbagh MN, Shill HA, Adler CH. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat Disord 2007 Aug; 13(6):348-54. Epub 2007 Mar 08.
    View PubMed
  25. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007 Jul 15; 22(9):1272-7.
    View PubMed
  26. Trosch RM, Adler CH, Pappert EJ. Botulinum toxin type B (Myobloc(R)) in subjects with hemifacial spasm: Results from an open-label, dose-escalation safety study. Mov Disord 2007 Jul 15; 22(9):1258-64.
    View PubMed
  27. Melquist S, Craig DW, Huentelman MJ, Crook R, Pearson JV, Baker M, Zismann VL, Gass J, Adamson J, Szelinger S, Corneveaux J, Cannon A, Coon KD, Lincoln S, Adler C, Tuite P, Calne DB, Bigio EH, Uitti RJ, Wszolek ZK, Golbe LI, Caselli RJ, Graff-Radford N, Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet 2007 Apr; 80(4):769-78. Epub 2007 Mar 08.
    View PubMed
  28. Snyder CH, Adler CH. The patient with Parkinson's disease: part I-treating the motor symptoms; part II-treating the nonmotor symptoms. J Am Acad Nurse Pract 2007 Apr; 19(4):179-97.
    View PubMed
  29. Melquist S, Craig DW, Huentelman MJ, Crook R, Pearson JV, Baker M, Zismann VL, Gass J, Adamson J, Szelinger S, Corneveaux J, Cannon A, Coon KD, Lincoln S, Adler C, Tuite P, Calne DB, Bigio EH, Uitti RJ, Wszolek ZK, Golbe LI, Caselli RJ, Graff-Radford N, L Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet 2007 Apr; 80(4):769-78.
  30. Toft M, Mata IF, Ross OA, Kachergus J, Hulihan MM, Haugarvoll K, Stone JT, Blazquez M, Gibson JM, Aasly JO, White LR, Lynch T, Adler CH, Gwinn-Hardy K, Farrer MJ. Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. Mov Disord 2007 Feb 15; 22(3):389-92.
    View PubMed
  31. Sabbagh MN, Lahti T, Connor DJ, Caviness JN, Shill H, Vedders L, Mahant P, Samanta J, Burns RS, Evidente VG, Driver-Dunckley E, Reisberg B, Bircea S, Adler CH. Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 24(5):327-34. Epub 2007 Sep 13.
    View PubMed
  32. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007; 68:20-8.
  33. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006 Dec 26; 67(12):2233-5.
    View PubMed
  34. Driver-Dunckley E, Evidente VG, Adler CH, Hillman R, Hernandez J, Fletcher G, Lyons MK. Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation. Mov Disord 2006 Aug; 21(8):1287-9.
    View PubMed
  35. Caviness JN, Shill HA, Sabbagh MN, Evidente VG, Hernandez JL, Adler CH. Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease. Mov Disord 2006 Apr; 21(4):492-9.
    View PubMed
  36. Caviness JN, Liss JM, Adler C, Evidente V. Analysis of high-frequency electroencephalographic-electromyographic coherence elicited by speech and oral nonspeech tasks in Parkinson's disease. J Speech Lang Hear Res 2006 Apr; 49(2):424-38.
    View PubMed
  37. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF, Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006 Mar 14; 66(5):672-7. Epub 2006 Jan 25.
    View PubMed
  38. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF, Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006 Mar 14; 66(5):672-7 Epub 2006 Jan 25.
    View PubMed
  39. Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, Pagano M, Parkinson Study Group. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 2006 Feb; 63(2):210-6.
    View PubMed
  40. Mata IF, Bodkin CL, Adler CH, Lin SC, Uitti RJ, Farrer MJ, Wszolek ZK. Genetics of restless legs syndrome. Parkinsonism Relat Disord 2006 Jan; 12(1):1-7.
    View PubMed
  41. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66:664-71.
  42. Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF, On behalf of the Topirimate Essential Tremor Study Investigators. Topirimate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006; 66:672-7.
  43. Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I, Day D, Shinaman A, Lew M, Kawai C, Hurtig H, Lloyd M, Hauser R, Gauger L, Wood R, Golbe L, Wojcieszek J, Belden J, Feigin A, Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006; 21(5):616-23.
    View PubMed
  44. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W, Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005 Nov 8; 65(9):1423-9.
    View PubMed
  45. Sabbagh MN, Silverberg N, Bircea S, Majeed B, Samant S, Caviness JN, Reisberg B, Adler CH. Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord 2005 Aug; 11(5):311-5.
    View PubMed
  46. Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H, The United States-Venezuela Huntington's Disease Collaborative Research Group, The Huntington Study Group. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord 2005 Mar; 20(3):293-7.
    View PubMed
  47. Wunderlich GR, Evans KR, Sills T, Pollentier S, Reess J, Allen RP, Hening W, Walter AS, The International Restless Legs Syndrome Study Group. An item response analysis of the international restless legs syndrome study group rating scale for restless legs syndrome. Sleep med 2005 Mar; 6(2):131-9.
  48. Toft M, Aasly J, Bisceglio G, Adler CH, Uitti RJ, Krygowska-Wajs A, Lynch T, Wszolek ZK, Farrer MJ. Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord 2005 Feb; 20(2):230-3.
    View PubMed
  49. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, Edwards BW, Krein-Jones K, Caviness JN. Botulinum toxin type A for treating voice tremor. Arch Neurol 2004 Sep; 61(9):1416-20.
    View PubMed
  50. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson WM, Hentz JG. Ropinirole for restless legs syndrome - A placebo-controlled crossover trial. Neurology 2004 Apr 27; 62(8):1405-7.
    View PubMed
  51. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498-2508.
    View PubMed
  52. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-synuclein locus triplication causes Parkinson's disease. Science 2003 Oct 31; 302(5646):841.
    View PubMed
  53. Caviness JN, Adler CH, Sabbagh MN, Connor DJ, Hernandez JL, Lagerlund TD. Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease. Mov Disord 2003 Oct; 18(10):1157-62.
    View PubMed
  54. Evidente VGH, Caviness JN, Adler CH. Case studies in movement disorders. Semin Neurol 2003 Sep; 23(3):277-84.
    View PubMed
  55. Beach TG, Sue L, Scott S, Layne K, Newell A, Walker D, Baker M, Sahara N, Yen SH, Hutton M, Caselli R, Adler C, Connor D, Sabbagh M. Hippocampal sclerosis dementia with tauopathy. Brain Pathol 2003 Jul; 13(3):263-78.
    View PubMed
  56. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003 Mar; 18(3):287-93.
    View PubMed
  57. Thorpy MJ, Adler CH. Awake and Involved: Addressing excessive daytime sleepiness in patients with Parkinson’s disease, Sleep issues in Parkinson’s disease (Review Article). The Treatment Reporter Neurology 2003; Part 2.
    View PubMed
  58. Adler CH, Thorpy MJ. Awake and Involved: Addressing excessive daytime sleepiness in patients with Parkinson’s disease, Overview of Parkinson’s disease (Review Article). The Treatment Reporter Neurology 2003(Part 1).
    View PubMed
  59. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montlaisir J, the participants in the RLS Diagnosis Epidemiology workshop at the NIH, in collaboration with members of the International RLS Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health Sleep Medicine 2003; 4:101-19.
  60. Liss JM, Spitzer SM, Caviness JN, Adler C. The effects of familiarization on intelligibility and lexical segmentation in hypokinetic and ataxic dysarthria. J Acoust Soc Am 2002 Dec; 112(6):3022-30.
    View PubMed
  61. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism & Related Disorders 2002 Dec; 9(2):103-10.
    View PubMed
  62. Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D-3 and not D-2 receptors. Brain Res 2002 Nov 15; 955(1-2):138-52.
    View PubMed
  63. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Small-amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations. Mov Disord 2002 Jul; 17(4):657-62.
    View PubMed
  64. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 2002 May 14; 58(9):1418-22.
    View PubMed
  65. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Hentz JG, Manfred MS, Muenter D. Motor unit number estimates in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2002 Jan; 8(3):161-4.
    View PubMed
  66. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson’s disease: The TEMPO study. Arch Neurol 2002; 59:1937-43.
    View PubMed
  67. Adler CH. Managing movement disorders with botulinum toxins: An effective approach for dystonia, tics, tremor, and hemifacial spasm (Review Article). Women’s Health in Primary Care 2002; 5:707-19.
    View PubMed
  68. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Myoclonus in Lewy body disorders. Adv Neurol 2002; 89:23-30.
    View PubMed
  69. Adler CH, Joyce JN. Collaboration Amongst Arizona Parkinson’s Disease Research Centers-Parkinson’s Disease Center Without Walls (Review Article). AZ Parkinson’s Disease Report 2002.
    View PubMed
  70. Evidente VGH, Caviness JN, Adler CH, Gwinn-Hardy KA, Pratley RE. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Mov Disord 2001 Sep; 16(5):924-927.
    View PubMed
  71. Joyce JN, Ryoo H, Gurevich EV, Adler C, Beach T. Ventral striatal D-3 receptors and Parkinson's disease. Parkinsonism & Related Disorders 2001 Jul; 7(3):225-230.
    View PubMed
  72. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001 Jun 12; 56(11):1523-8.
    View PubMed
  73. Shoulson I, Penney J, McDermott M, Kieburtz K, Schwid SR, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost-Ruffner E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Fac A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001 Feb 27; 56(4):455-462.
    View PubMed
  74. Adler CH. Ten commonly asked questions about initiating treatment for Parkinson’s disease (Review Article). The Neurologist 2001; 7(3):188-92.
    View PubMed
  75. Weiner WJ, The Pramipexole Study Group. The long-term safety and efficacy of pramipexole in advanced Parkinson’s disease. Parkinsonism and Related Disorders 2001; 7:115-20.
    View PubMed
  76. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Hentz JG, Muenter MD. Motor Unit Number Estimates in Idiopathic Parkinson’s Disease. Parkinsonism and Related Disorders 2001; 8:161-4.
    View PubMed
  77. Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I, The Huntington Study Group. Clinical markers of early disease in persons near onset of Huntington’s disease. Neurology. 2001 Aug 28;57(4):658-62.
    View PubMed
  78. Adler CH. Diagnosing and treating restless legs syndrome (Review Article). Women’s Health In Primary Care 2001; 4:224-8.
    View PubMed
  79. Adler CH. Diagnosing and treating restless legs syndrome (Review Article). Women’s Health Gynecology Edition 2001; 1:371-8.
    View PubMed
  80. Pennachio DL, Consultants. Parkinson’s disease: Progress along the continuum of care (Review Article). Patient Care 2000 Dec.
    View PubMed
  81. Cooper C, Evidente VG, Hentz JG, Adler CH, Caviness JN, Gwinn-Hardy K. The effect of temperature on hand function in patients with tremor. J Hand Ther 2000 Oct-Dec; 13(4):276-88.
    View PubMed
  82. Adler CH. Strategies for controlling dystonia. Overview of therapies that may alleviate symptoms. Postgrad Med 2000 Oct; 108(5):151-2, 155-6, 159-60..
    View PubMed
  83. Liss JM, Spitzer SM, Caviness JN, Adler C, Edwards BW. Lexical boundary error analysis in hypokinetic and ataxic dysarthria. J Acoust Soc Am 2000 Jun; 107(6):3415-24.
    View PubMed
  84. Evidente VG, Adler CH, Caviness JN, Hentz JG, Gwinn-Hardy K. Amantadine is beneficial in restless legs syndrome. Mov Disord 2000 Mar; 15(2):324-7.
    View PubMed
  85. Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Reiners CA, Hentz JG, Muenter MD. Motor unit changes in sporadic idiopathic Parkinson's disease. Mov Disord 2000 Mar; 15(2):238-43.
    View PubMed
  86. Gwinn-Hardy KA, Crook R, Lincoln S, Adler CH, Caviness JN, Hardy J, Farrer M. A kindred with Parkinson's disease not showing genetic linkage to established loci. Neurology 2000 Jan 25; 54(2):504-7.
    View PubMed
  87. Caviness JN, Gwinn-Hardy K, Adler CH, Muenter MD. Electrophysical observations in hereditary Parkinsonism-dementia with Lewy body pathology. Mov Disord 2000 Jan; 15(1):140-145.
    View PubMed
  88. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Siemers E, Shoulson I, Caviness JN, The Huntington Study Group. Rate of functional decline in Huntington’s disease. Neurology 2000; 54:452-8.
    View PubMed
  89. Joyce JN, Adler CH. Research for new treatment of Parkinson’s disease (Review Article). Southwest Parkinson Report 2000 Spr/Sum.
    View PubMed
  90. Evidente VG, Gwinn-Hardy K, Caviness JN, Adler CH. Risperidone is effective in severe hemichorea/hemiballismus. Mov Disord 1999 Mar; 14(2):377-9.
    View PubMed
  91. Evidente VG, Adler CH, Caviness JN, Gwinn-Hardy K. A pilot study on the motor effects of rimantadine in Parkinson's disease. Clin Neuropharmacol 1999 Jan-Feb; 22(1):30-2.
    View PubMed
  92. Liss JM, Spitzer S, Caviness JN, Adler C, Edwards B. Syllabic strength and lexical boundary decisions in the perception of hypokinetic dysarthric speech. J Acoust Soc Am 1998 Oct; 104(4):2457-66.
    View PubMed
  93. Evidente VG, Adler CH, Caviness JN, Gwinn KA. Effective treatment of orthostatic tremor with gabapentin. Mov Disord 1998 Sep; 13(5):829-31.
    View PubMed
  94. Caviness JN, Adler CH, Newman S, Caselli RJ, Muenter MD. Cortical myoclonus in levodopa-responsive parkinsonism. Mov Disord 1998 May; 13(3):540-4.
    View PubMed
  95. Evidente VG, Adler CH, Giannini C, Conley CR, Parisi JE, Fletcher GP. Erdheim-Chester disease with extensive intraaxial brain stem lesions presenting as a progressive cerebellar syndrome. Mov Disord 1998 May; 13(3):576-81.
    View PubMed
  96. Uitti RJ, Wharen RE Jr, Turk MF, Lucas JA, Finton MJ, Graff-Radford NR, Boylan KB, Goerss SJ, Kall BA, Adler CH, Caviness JN, Atkinson EJ. Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients. Neurology 1997 Oct; 49(4):1072-7.
    View PubMed
  97. Adler CH, Caviness JN. Dystonia secondary to electrical injury: surface electromyographic evaluation and implications for the organicity of the condition. J Neurol Sci 1997 May 29; 148(2):187-92.
    View PubMed
  98. Kurth MC, Adler CH, Sthilaire M, Singer C, Waters C, Lewitt P, Chernik DA, Dorflinger EE, Yoo K, Lieberman AN, Brewer M, Sainthilaire M, Pery LM, Thomas C, Turpin L, Obrien CF, Seeberger LC, Duncan KL, Caviness JN, Douglas M, Wheeler K, Riley D, Rainey P, Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations - a multicenter, double blind, randomized, placebo-controlled trial. Neurology 1997 Jan; 48(1):81-87.
    View PubMed
  99. Lieberman A, Caviness JN, The Pramipexole Study Group. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controled, parallel-group study. Neurology 1997; 49(162-8).
  100. Bernardi B, Zimmerman RA, Savino PJ, Adler C. Magnetic resonance tomographic angiography in the investigation of hemifacial spasm. Neuroradiology 1993; 35(8):606-11.
    View PubMed
  101. Snyder CH, Adler CH. The patient with Parkinson's disease: Part I - Treating the motor symptoms. J Am Acad Nurse Practitioners 2007; 19:179-88.
    View PubMed
  102. Snyder CH, Adler CH. The patient with Parkinson's disease: Part II - Treating the nonmotor symptoms. J Am Acad Nurse Practitioners 2007; 19:189-97.
    View PubMed


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.